Ardelyx (ARDX) Times Interest Earned (2013 - 2026)
Ardelyx's (ARDX) quarterly Times Interest Earned came in at -$6.36 in Q1 2026, up 26.65% YoY from -$5.02 in Q1 2025, and down 654.41% on a QoQ basis from -$0.84 in Q4 2025.
Ardelyx (ARDX) Times Interest Earned (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Times Interest Earned data on file, last reported at -$6.36 in Q1 2026.
- Quarterly Times Interest Earned rose 26.65% year-over-year to -$6.36 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.26 (down 194.72% YoY) and the FY2025 annual result came in at -$0.19, down 39.25% from the prior year.
- Times Interest Earned fell to -$6.36 in Q1 2026, from -$0.84 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $6.61 in Q3 2023 to a low of -$41.44 in Q4 2022.
- A 5-year average of -$12.5 and a median of -$8.67 in 2025 frame the typical range for Times Interest Earned.
- The widest YoY moves for Times Interest Earned: up 220.73% in 2025, down 164.41% in 2025.
- Tracing ARDX's Times Interest Earned over 5 years: stood at -$41.44 in 2022, then climbed by 26.92% to -$30.29 in 2023, then surged by 104.32% to $1.31 in 2024, then plunged by 164.41% to -$0.84 in 2025, then tumbled by 654.41% to -$6.36 in 2026.
- The last three Times Interest Earned figures came in at -$6.36 (Q1 2026), -$0.84 (Q4 2025), and $2.13 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | -2.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.51 |
| Mar 31, 2026 | -6.36 |
| Dec 31, 2025 | -0.84 |
| Sep 30, 2025 | 2.13 |
| Jun 30, 2025 | -7.84 |
| Mar 31, 2025 | -8.67 |
| Dec 31, 2024 | 1.31 |
| Sep 30, 2024 | 0.67 |
| Jun 30, 2024 | -5.84 |
| Mar 31, 2024 | -11.78 |
| Dec 31, 2023 | -30.29 |
| Sep 30, 2023 | 6.61 |
| Jun 30, 2023 | -15.11 |
| Mar 31, 2023 | -23.74 |
| Dec 31, 2022 | -41.44 |
| Sep 30, 2022 | -20.41 |
| Jun 30, 2022 | -24.64 |
| Mar 31, 2022 | -26.28 |
| Dec 31, 2021 | -35.85 |
| Sep 30, 2021 | -34.73 |